BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37

Benzinga · 3d ago
BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $28 to $37.